Beam Therapeutics
BEAM
240 hedge funds and large institutions have $2.82B invested in Beam Therapeutics in 2022 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 96 increasing their positions, 44 reducing their positions, and 37 closing their positions.
118% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 44
32% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 37
4.78% more ownership
Funds ownership: 66.84% → 71.62% (+4.8%)
3% more funds holding
Funds holding: 232 → 240 (+8)
22% less capital invested
Capital invested by funds: $3.63B → $2.82B (-$806M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
50% less call options, than puts
Call options by funds: $21.5M | Put options by funds: $42.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$98M |
| 2 |
Temasek Holdings
Singapore
|
+$32.9M |
| 3 |
Millennium Management
New York
|
+$28.7M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$21.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$19.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$26.9M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$10.2M |
| 3 |
Goldman Sachs
New York
|
-$9.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.69M |
| 5 |
E
Ergoteles
New York
|
-$3.55M |
BEAM Hedge Fund Activity: Q1 2022 in Review
240 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q1 2022, worth a combined $2.82B — down 22% from $3.63B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new BEAM positions and 37 closed out — a net gain of 12 holders — while 96 added to existing stakes and 44 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $98M. The largest seller was Cormorant Asset Management, cutting an estimated $26.9M.
- 240 institutional investors held Beam Therapeutics (BEAM) as of Q1 2022, up from 232 in Q4 2021.
- Funds reported $2.82B of Beam Therapeutics stock for Q1 2022, down 22% quarter-over-quarter.
- 49 funds opened new Beam Therapeutics positions in Q1 2022 and 37 closed out, a net change of +12 holders.
- The largest Beam Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $98M added.
- The largest Beam Therapeutics seller in Q1 2022 was Cormorant Asset Management, an estimated $26.9M sold.
Based on aggregated 13F filings for Q1 2022.